Total Payments
$309,966
2024 Payments
$49,373
Companies
44
Transactions
1,211
Medicare Patients
14,564
Medicare Billing
$2.4M
Payment Breakdown by Category
Other$246,424 (79.5%)
Food & Beverage$22,166 (7.2%)
Research$16,373 (5.3%)
Travel$12,378 (4.0%)
Consulting$12,140 (3.9%)
Education$431.42 (0.1%)
Gifts$53.32 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $246,424 | 115 | 79.5% |
| Food and Beverage | $22,166 | 1,004 | 7.2% |
| Unspecified | $16,373 | 11 | 5.3% |
| Travel and Lodging | $12,378 | 54 | 4.0% |
| Consulting Fee | $12,140 | 12 | 3.9% |
| Education | $431.42 | 14 | 0.1% |
| Gift | $53.32 | 1 | 0.0% |
Payments by Type
General
$293,593
1,200 transactions
Research
$16,373
11 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| ABBVIE INC. | $146,027 | 414 | $0 (2024) |
| Gilead Sciences, Inc. | $72,089 | 128 | $0 (2024) |
| Phathom Pharmaceuticals, Inc. | $23,273 | 43 | $0 (2024) |
| Eli Lilly and Company | $13,937 | 10 | $0 (2021) |
| Synergy Pharmaceuticals Inc | $9,671 | 27 | $0 (2018) |
| Merck Sharp & Dohme LLC | $7,149 | 35 | $0 (2024) |
| RedHill Biopharma Inc. | $7,048 | 31 | $0 (2024) |
| Allergan, Inc. | $5,385 | 16 | $0 (2020) |
| IRONWOOD PHARMACEUTICALS, INC | $4,657 | 53 | $0 (2024) |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | $3,299 | 86 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $49,373 | 226 | Phathom Pharmaceuticals, Inc. ($23,273) |
| 2023 | $26,586 | 146 | ABBVIE INC. ($15,257) |
| 2022 | $30,717 | 145 | ABBVIE INC. ($18,331) |
| 2021 | $29,217 | 141 | AbbVie Inc. ($10,015) |
| 2020 | $24,910 | 100 | AbbVie Inc. ($11,811) |
| 2019 | $48,269 | 158 | AbbVie, Inc. ($27,191) |
| 2018 | $59,630 | 144 | AbbVie, Inc. ($34,037) |
| 2017 | $41,264 | 151 | AbbVie, Inc. ($19,022) |
All Payment Transactions
1,211 individual payment records from CMS Open Payments — Page 1 of 49
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/27/2024 | ABBVIE INC. | RINVOQ (Biological), SKYRIZI | Food and Beverage | In-kind items and services | $22.42 | General |
| Category: IMMUNOLOGY | ||||||
| 12/27/2024 | ABBVIE INC. | RINVOQ (Biological), SKYRIZI | Food and Beverage | In-kind items and services | $3.20 | General |
| Category: IMMUNOLOGY | ||||||
| 12/21/2024 | ABBVIE INC. | RINVOQ (Biological), SKYRIZI | Food and Beverage | In-kind items and services | $23.57 | General |
| Category: IMMUNOLOGY | ||||||
| 12/19/2024 | Phathom Pharmaceuticals, Inc. | VOQUEZNA (Drug) | Food and Beverage | In-kind items and services | $16.67 | General |
| Category: GASTROENTEROLOGY | ||||||
| 12/19/2024 | Phathom Pharmaceuticals, Inc. | VOQUEZNA (Drug) | Food and Beverage | In-kind items and services | $14.19 | General |
| Category: GASTROENTEROLOGY | ||||||
| 12/18/2024 | Lilly USA, LLC | OMVOH (Drug) | Food and Beverage | In-kind items and services | $24.33 | General |
| Category: Immunology | ||||||
| 12/18/2024 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | XIFAXAN (Drug) | Food and Beverage | In-kind items and services | $11.65 | General |
| Category: Gastroenterology | ||||||
| 12/18/2024 | Janssen Biotech, Inc. | TREMFYA (Drug) | Food and Beverage | In-kind items and services | $8.82 | General |
| Category: Immunology | ||||||
| 12/18/2024 | Janssen Biotech, Inc. | TREMFYA (Drug) | Food and Beverage | In-kind items and services | $1.20 | General |
| Category: Immunology | ||||||
| 12/17/2024 | ABBVIE INC. | MAVYRET (Drug) | Food and Beverage | In-kind items and services | $22.89 | General |
| Category: VIROLOGY | ||||||
| 12/17/2024 | ABBVIE INC. | LINZESS (Drug), VIBERZI | Food and Beverage | In-kind items and services | $13.11 | General |
| Category: GASTROENTEROLOGY | ||||||
| 12/16/2024 | AIMMUNE THERAPEUTICS, INC. | VOWST (Biological) | Food and Beverage | In-kind items and services | $16.66 | General |
| Category: GI | ||||||
| 12/12/2024 | Regeneron Healthcare Solutions, Inc. | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $36.06 | General |
| Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 12/09/2024 | Janssen Biotech, Inc. | TREMFYA (Drug) | Food and Beverage | In-kind items and services | $6.43 | General |
| Category: Immunology | ||||||
| 12/05/2024 | ABBVIE INC. | LINZESS (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,875.00 | General |
| Category: GASTROENTEROLOGY | ||||||
| 12/05/2024 | Ardelyx, Inc. | IBSRELA (Drug) | Food and Beverage | In-kind items and services | $33.75 | General |
| Category: GASTROENTEROLOGY | ||||||
| 12/05/2024 | Ardelyx, Inc. | IBSRELA (Drug) | Food and Beverage | In-kind items and services | $24.54 | General |
| Category: GASTROENTEROLOGY | ||||||
| 12/02/2024 | IRONWOOD PHARMACEUTICALS, INC | Linzess (Drug) | Food and Beverage | Cash or cash equivalent | $6.88 | General |
| Category: GI | ||||||
| 11/27/2024 | ABBVIE INC. | SKYRIZI (Biological) | Food and Beverage | In-kind items and services | $20.46 | General |
| Category: IMMUNOLOGY | ||||||
| 11/27/2024 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | XIFAXAN (Drug) | Food and Beverage | In-kind items and services | $16.95 | General |
| Category: Gastroenterology | ||||||
| 11/25/2024 | Madrigal Pharmaceuticals | RESMETIROM (Drug) | Food and Beverage | In-kind items and services | $26.26 | General |
| Category: LIVER DISEASE | ||||||
| 11/21/2024 | Janssen Biotech, Inc. | TREMFYA (Drug) | Food and Beverage | In-kind items and services | $33.10 | General |
| Category: Immunology | ||||||
| 11/21/2024 | ABBVIE INC. | CREON (Drug), LINZESS | Food and Beverage | In-kind items and services | $16.08 | General |
| Category: ENDOCRINOLOGY | ||||||
| 11/20/2024 | Madrigal Pharmaceuticals | RESMETIROM (Drug) | Food and Beverage | In-kind items and services | $26.77 | General |
| Category: LIVER DISEASE | ||||||
| 11/19/2024 | ABBVIE INC. | CREON (Drug) | Food and Beverage | In-kind items and services | $10.48 | General |
| Category: ENDOCRINOLOGY | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A PHASE 3B, RANDOMIZED, DOUBLE-BLIND, PARALLEL-ARM, PLACEBO- AND ACTIVE- CONTROLLED TREAT-THROUGH STUDY OF MIRIKIZUMAB AND VEDOLIZUMAB IN PARTICIPANTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS | Eli Lilly and Company | $6,520 | 1 |
| A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis | Bausch Health US, LLC | $2,437 | 1 |
| A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO- AND ACTIVE- CONTROLLED, TREAT-THROUGH STUDY TO EVALUATE THE EFFICACY AND SAFETY OF MIRIKIZUMAB IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN'S DISEASE | Eli Lilly and Company | $2,314 | 2 |
| A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PARALLEL, PLACEBO-CONTROLLED INDUCTION STUDY OF MIRIKIZUMAB IN CONVENTIONAL-FAILED AND BIOLOGIC-FAILED PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS (LUCENT 1) | Eli Lilly and Company | $2,263 | 3 |
| A PHASE 3, MULTICENTER, OPEN-LABEL EXTENSION STUDY TO EVALUATE THE LONG TERM EFFICACY AND SAFETY OF MIRIKIZUMAB IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS LUCENT 3 | Eli Lilly and Company | $1,691 | 2 |
| A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PARALLEL-ARM, PLACEBO-CONTROLLED MAINTENANCE STUDY OF MIRIKIZUMAB IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS (LUCENT 2) | Eli Lilly and Company | $1,148 | 2 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 34 | 3,839 | 6,860 | $3.9M | $609,675 |
| 2022 | 32 | 3,897 | 6,591 | $2.6M | $624,458 |
| 2021 | 36 | 3,675 | 5,843 | $2.1M | $642,130 |
| 2020 | 33 | 3,153 | 4,327 | $1.9M | $558,388 |
Total Patients
14,564
Total Services
23,621
Medicare Billing
$2.4M
Procedure Codes
135
All Medicare Procedures & Services
135 procedure records from CMS Medicare Utilization — Page 1 of 6
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 46221 | Removal of external hemorrhoids by rubber banding | Office | 2023 | 215 | 513 | $728,460 | $125,610 | 17.2% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 452 | 597 | $358,200 | $62,109 | 17.3% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 642 | 872 | $383,680 | $61,984 | 16.2% |
| 99439 | Chronic care management services for two or more chronic conditions, additional 20 minutes of clinical staff time directed by health care professional, per calendar month | Office | 2023 | 149 | 1,427 | $342,480 | $57,562 | 16.8% |
| 45385 | Removal of polyps or growths of large bowel using an endoscope with mechanical snare | Facility | 2023 | 207 | 213 | $249,932 | $44,538 | 17.8% |
| 99490 | Chronic care management services, first 20 minutes of clinical staff time directed by health care professional, per calendar month | Office | 2023 | 149 | 843 | $252,900 | $44,225 | 17.5% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 333 | 333 | $259,740 | $42,250 | 16.3% |
| 43239 | Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | Facility | 2023 | 421 | 440 | $264,706 | $22,727 | 8.6% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 116 | 126 | $72,179 | $13,374 | 18.5% |
| 45380 | Biopsy of large bowel using a flexible endoscope | Facility | 2023 | 158 | 159 | $176,306 | $13,322 | 7.6% |
| 46600 | Diagnostic exam of anus using an endoscope | Office | 2023 | 118 | 120 | $76,800 | $11,514 | 15.0% |
| 99231 | Subsequent hospital care with straightforward or low level of medical decision making, per day, if using time, at least 25 minutes | Facility | 2023 | 92 | 253 | $56,338 | $10,418 | 18.5% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2023 | 112 | 112 | $60,480 | $9,020 | 14.9% |
| 43251 | Removal of polyps or growths of esophagus, stomach, and/or upper small bowel using an endoscope with mechanical snare | Facility | 2023 | 58 | 59 | $48,973 | $8,349 | 17.0% |
| G0105 | Colorectal cancer screening; colonoscopy on individual at high risk | Facility | 2023 | 48 | 48 | $38,378 | $8,339 | 21.7% |
| 91110 | Imaging of digestive tract done from the inside of the digestive tract | Office | 2023 | 11 | 12 | $47,760 | $7,779 | 16.3% |
| 43248 | Insertion of guide wire with dilation of esophagus using a flexible endoscope | Facility | 2023 | 78 | 79 | $57,399 | $7,768 | 13.5% |
| G0121 | Colorectal cancer screening; colonoscopy on individual not meeting criteria for high risk | Facility | 2023 | 40 | 40 | $62,245 | $7,006 | 11.3% |
| 43264 | Removal of stone or debris from bile or pancreatic duct using a flexible endoscope | Facility | 2023 | 22 | 22 | $34,086 | $5,825 | 17.1% |
| 99496 | Transitional care management services for problem of high complexity | Office | 2023 | 22 | 22 | $29,040 | $5,309 | 18.3% |
| 45378 | Diagnostic exam of large bowel using a flexible endoscope | Facility | 2023 | 36 | 37 | $29,554 | $5,138 | 17.4% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 33 | 34 | $24,654 | $4,795 | 19.4% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 47 | 72 | $25,605 | $4,741 | 18.5% |
| 43255 | Control of bleeding of esophagus, stomach, and/or upper small bowel using a flexible endoscope | Facility | 2023 | 27 | 27 | $23,162 | $4,252 | 18.4% |
| 99454 | Remote monitoring of physiologic parameters, initial supply of devices with daily recordings or programmed alerts transmission, each 30 days | Office | 2023 | 18 | 86 | $24,080 | $3,950 | 16.4% |
About Dr. Jatinder Pruthi, M.D
Dr. Jatinder Pruthi, M.D is a Gastroenterology healthcare provider based in Lancaster, California. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/14/2006. The National Provider Identifier (NPI) number assigned to this provider is 1205852985.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Jatinder Pruthi, M.D has received a total of $309,966 in payments from pharmaceutical and medical device companies, with $49,373 received in 2024. These payments were reported across 1,211 transactions from 44 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($246,424).
As a Medicare-enrolled provider, Pruthi has provided services to 14,564 Medicare beneficiaries, totaling 23,621 services with total Medicare billing of $2.4M. Data is available for 4 years (2020–2023), covering 135 distinct procedure/service records.
Ad
Practice Information
- Specialty Gastroenterology
- Location Lancaster, CA
- Active Since 07/14/2006
- Last Updated 11/19/2012
- Taxonomy Code 207RG0100X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1205852985
Products in Payments
- Epclusa (Drug) $54,948
- Mavyret (Drug) $53,845
- MAVYRET (Drug) $42,866
- VOQUEZNA (Drug) $23,273
- LINZESS (Drug) $14,975
- Trulance (Drug) $9,671
- Humira (Biological) $7,680
- ZEPATIER (Drug) $6,748
- XIFAXAN (Drug) $5,491
- Talicia (Drug) $5,241
- HUMIRA (Biological) $5,076
- Vosevi (Drug) $4,454
- Viekira (Drug) $4,207
- Linzess (Drug) $4,083
- Doptelet (Drug) $3,231
- IBSRELA (Drug) $1,839
- TALICIA (Drug) $1,665
- CREON (Drug) $1,545
- STELARA (Biological) $1,382
- ESOPHYX (Device) $607.18
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Gastroenterology Doctors in Lancaster
Dr. John Betteridge, M.d, M.D
Gastroenterology — Payments: $319,302
Gastroenterology $319,302
Dr. Paul Allegretti, D.o, D.O
Gastroenterology — Payments: $100,281
Gastroenterology $100,281
Justin Harberson, M.d, M.D
Gastroenterology — Payments: $63,699
Gastroenterology $63,699
Vivaik Tyagi, M.d, M.D
Gastroenterology — Payments: $40,947
Gastroenterology $40,947
Kaci Christian, M.d, M.D
Gastroenterology — Payments: $28,028
Gastroenterology $28,028
Dr. Vimal Amin, Md, MD
Gastroenterology — Payments: $15,316
Gastroenterology $15,316